Association of HLA-B35 with mucocutaneous lesions in Israeli patients with rheumatoid arthritis receiving gold treatment.
Seventy-four Israeli patients with rheumatoid arthritis (RA) were studied for possible association between HLA antigens and adverse reactions to gold treatment (aurothioglucose). HLA-B35 was significantly increased in patients who developed gold induced mucocutaneous lesions. These results are in accord with earlier reports, despite the different genetic background of the Israeli RA population and the different type of gold compound used.
Tishler
M
M
Department of Rheumatology, Tel Aviv Medical Center, Israel.
Caspi
D
D
Gazit
E
E
Yaron
M
M
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D006051:Aurothioglucose / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000235:genetics / Q000276:immunology; D005260:Female; D006046:Gold / Q000009:adverse effects*; D006680:HLA Antigens / Q000032:analysis*; D015797:HLA-B35 Antigen; D006801:Humans; D008297:Male; D008875:Middle Aged; D013281:Stomatitis, Aphthous / Q000139:chemically induced* / Q000235:genetics / Q000276:immunology
D006680:HLA Antigens; D015797:HLA-B35 Antigen; D006051:Aurothioglucose; D006046:Gold